Metabolon Reaches Diabetes Research Deals in Mexico | GenomeWeb

NEW YORK (GenomeWeb News) – Metabolon today announced research collaborations and a licensing agreement aimed at diabetes in Mexico and Latin America.

As part of the multiyear, royalty-based research collaborations, Metabolon's Quantose IR technology will be used in several diabetes prevention studies in Mexico. The licensing deal with Patia Biopharma provides exclusive access in Mexico to Metabolon's prediabetes technology for evaluating insulin resistance in Mexico through Patia and Clinica Ruiz's laboratory network.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.